Thermo Fisher Scientific

Shortcut’s reasoning.

The segment build forecasts $11.97bn revenue and $2.385bn adjusted net income. Segment margins, financing, an 11.5% adjusted tax rate and 370.547m diluted shares produce EPS of $6.44 versus the Street estimate of $6.40.

Segment income and margins drive earnings; detailed expense allocations are illustrative. The normalized bridge excludes the estimated Microbiology divestiture gain, whose actual GAAP treatment remains uncertain.

Cash-flow classifications and asset allocations remain simplified. These additional metrics are tracked, not scored. The original EPS assumptions were preserved through both repair rounds.